As of Dec 02
| +0.0038 / +1.26%|
The 3 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 1.00, with a high estimate of 1.50 and a low estimate of 0.50. The median estimate represents a +228.08% increase from the last price of 0.30.
The current consensus among 3 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.